Based on the Theravance Biopharma Inc stock forecast from 3 analysts, the average analyst target price for Theravance Biopharma Inc is USD 12.50 over the next 12 months. Theravance Biopharma Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Theravance Biopharma Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Theravance Biopharma Inc’s stock price was USD 9.72. Theravance Biopharma Inc’s stock price has changed by +0.93% over the past week, +4.40% over the past month and +9.83% over the last year.
No recent analyst target price found for Theravance Biopharma Inc
No recent average analyst rating found for Theravance Biopharma Inc
Company Overview Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. Read Less
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary ...Read More
Frequently Asked Questions About Theravance Biopharma Inc (TBPH) Stock
Based on ratings from 3 analysts Theravance Biopharma Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on TBPH's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for TBPH is USD 12.50 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on TBPH's stock to indicate if its overvalued.
The last closing price of TBPH's stock was USD 9.72.
The most recent market capitalization for TBPH is USD 0.51B.
Based on targets from 3 analysts, the average taret price for TBPH is projected at USD 12.50 over the next 12 months.
This means that TBPH's stock price may go up by +28.60% over the next 12 months.
We can't find any ETFs which contains Theravance Biopharma Inc's stock.
As per our most recent records Theravance Biopharma Inc has 99 Employees.
Theravance Biopharma Inc's registered address is 901 Gateway Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Theravance Biopharma Inc's website at https://www.theravance.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Theravance Biopharma Inc (TBPH) Stock
Based on ratings from 3 analysts Theravance Biopharma Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on TBPH's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for TBPH is USD 12.50 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on TBPH's stock to indicate if its overvalued.
The last closing price of TBPH's stock was USD 9.72.
The most recent market capitalization for TBPH is USD 0.51B.
Based on targets from 3 analysts, the average taret price for TBPH is projected at USD 12.50 over the next 12 months.
This means that TBPH's stock price may go up by +28.60% over the next 12 months.
We can't find any ETFs which contains Theravance Biopharma Inc's stock.
As per our most recent records Theravance Biopharma Inc has 99 Employees.
Theravance Biopharma Inc's registered address is 901 Gateway Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Theravance Biopharma Inc's website at https://www.theravance.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TBPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
